TY - JOUR
T1 - Clinicopathological characteristics in combined hepatocellular-cholangiocarcinoma
T2 - A single center study in Korea
AU - Park, Hana
AU - Choi, Ki Hong
AU - Choi, Sae Byeol
AU - Choi, Jong Won
AU - Kim, Do Young
AU - Ahn, Sang Hoon
AU - Kim, Kyung Sik
AU - Choi, Jin Sub
AU - Han, Kwang Hyub
AU - Chon, Chae Yoon
AU - Park, Jun Yong
PY - 2011/9
Y1 - 2011/9
N2 - Purpose: Combined hepatocellular-cholangiocarcinoma (CHCC) is an uncommon form of cancer, and its clinicopathological features have rarely been reported in detail. This study was undertaken to evaluate the clinicopathological characteristics and prognostic factors of CHCC. Materials and Methods: The clinicopathological features of patients diagnosed with CHCC at Severance Hospital between January 1996 and December 2007 were retrospectively studied by comparing them with the features of patients with hepatocellular carcinoma (HCC) or cholangiocarcinoma (CC) who had undergone a hepatic resection during the same period. Results: Forty-three patients diagnosed with CHCC were included in this study (M: F=35: 8, median age, 55 years). According to the parameters of the American Joint Committee on Cancer staging, there were 6 (14.0%), 9 (20.9%), 25 (58.1%), and 3 (7.0%) patients with stages I, II, III, and IV cancer, respectively. Thirty-two of the 43 patients underwent resection with curative intent. After resection, 27 patients (84.4%) had tumor recurrence during the follow-up period of 18 months (range: 6-106 months), and the median time to recurrence was 13 months. Overall median survival periods after hepatic resection of CHCC, HCC and CC were 34, 103 and 38.9 months, respectively (p<0.001). The median overall survival for all patients with CHCC was 21 months, and the 5-year survival rate was 18.1%. The presence of portal vein thrombosis and distant metastasis were independent prognostic factors of poor survival. Conclusion: Even after curative hepatic resection, the presence of a cholangiocellular component appeared to be a poor prognostic indicator in patients with primary liver cancer.
AB - Purpose: Combined hepatocellular-cholangiocarcinoma (CHCC) is an uncommon form of cancer, and its clinicopathological features have rarely been reported in detail. This study was undertaken to evaluate the clinicopathological characteristics and prognostic factors of CHCC. Materials and Methods: The clinicopathological features of patients diagnosed with CHCC at Severance Hospital between January 1996 and December 2007 were retrospectively studied by comparing them with the features of patients with hepatocellular carcinoma (HCC) or cholangiocarcinoma (CC) who had undergone a hepatic resection during the same period. Results: Forty-three patients diagnosed with CHCC were included in this study (M: F=35: 8, median age, 55 years). According to the parameters of the American Joint Committee on Cancer staging, there were 6 (14.0%), 9 (20.9%), 25 (58.1%), and 3 (7.0%) patients with stages I, II, III, and IV cancer, respectively. Thirty-two of the 43 patients underwent resection with curative intent. After resection, 27 patients (84.4%) had tumor recurrence during the follow-up period of 18 months (range: 6-106 months), and the median time to recurrence was 13 months. Overall median survival periods after hepatic resection of CHCC, HCC and CC were 34, 103 and 38.9 months, respectively (p<0.001). The median overall survival for all patients with CHCC was 21 months, and the 5-year survival rate was 18.1%. The presence of portal vein thrombosis and distant metastasis were independent prognostic factors of poor survival. Conclusion: Even after curative hepatic resection, the presence of a cholangiocellular component appeared to be a poor prognostic indicator in patients with primary liver cancer.
KW - Cholangiocarcinoma
KW - Combined hepatocellular and cholangiocarcinoma
KW - Hepatocellular carcinoma
UR - http://www.scopus.com/inward/record.url?scp=79960989617&partnerID=8YFLogxK
U2 - 10.3349/ymj.2011.52.5.753
DO - 10.3349/ymj.2011.52.5.753
M3 - Review article
C2 - 21786439
AN - SCOPUS:79960989617
SN - 0513-5796
VL - 52
SP - 753
EP - 760
JO - Yonsei medical journal
JF - Yonsei medical journal
IS - 5
ER -